232 related articles for article (PubMed ID: 35721085)
21. Emerging Therapies in Cutaneous Lupus Erythematosus.
Sprow G; Dan J; Merola JF; Werth VP
Front Med (Lausanne); 2022; 9():968323. PubMed ID: 35899214
[TBL] [Abstract][Full Text] [Related]
22. Autoimmune Diseases in Patients With Cutaneous Lupus Erythematosus.
Kunzler E; Hynan LS; Chong BF
JAMA Dermatol; 2018 Jun; 154(6):712-716. PubMed ID: 29801110
[TBL] [Abstract][Full Text] [Related]
23. The role of cytokines in the pathogenesis of cutaneous lupus erythematosus.
Robinson ES; Werth VP
Cytokine; 2015 Jun; 73(2):326-34. PubMed ID: 25767072
[TBL] [Abstract][Full Text] [Related]
24. Increased cancer risk in patients with cutaneous lupus erythematosus and systemic lupus erythematosus compared with the general population: A Danish nationwide cohort study.
Westermann R; Zobbe K; Cordtz R; Haugaard JH; Dreyer L
Lupus; 2021 Apr; 30(5):752-761. PubMed ID: 33497306
[TBL] [Abstract][Full Text] [Related]
25. Cutaneous Lupus Erythematosus: Progress and Challenges.
Petty AJ; Floyd L; Henderson C; Nicholas MW
Curr Allergy Asthma Rep; 2020 Apr; 20(5):12. PubMed ID: 32248318
[TBL] [Abstract][Full Text] [Related]
26. Expression pattern of tissue-resident memory T cells in cutaneous lupus erythematosus.
Gu HJ; Song S; Roh JY; Jung Y; Kim HJ
Lupus; 2021 Aug; 30(9):1427-1437. PubMed ID: 34013817
[TBL] [Abstract][Full Text] [Related]
27. The classification and diagnosis of cutaneous lupus erythematosus.
Kuhn A; Landmann A
J Autoimmun; 2014; 48-49():14-9. PubMed ID: 24486120
[TBL] [Abstract][Full Text] [Related]
28. Higher specificity of the new EULAR/ACR 2019 criteria for diagnosing systemic lupus erythematosus in patients with biopsy-proven cutaneous lupus.
Stec-Polak M; Matyja-Bednarczyk A; Wojas-Pelc A; Pastuszczak M
Clin Exp Rheumatol; 2021; 39(5):955-960. PubMed ID: 32940207
[TBL] [Abstract][Full Text] [Related]
29. Immunologic and genetic considerations of cutaneous lupus erythematosus: a comprehensive review.
Yu C; Chang C; Zhang J
J Autoimmun; 2013 Mar; 41():34-45. PubMed ID: 23380467
[TBL] [Abstract][Full Text] [Related]
30. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus.
Szepietowski JC; Nilganuwong S; Wozniacka A; Kuhn A; Nyberg F; van Vollenhoven RF; Bengtsson AA; Reich A; de Vries DE; van Hartingsveldt B; Robinson DW; Gordon R; Hsu B
Arthritis Rheum; 2013 Oct; 65(10):2661-71. PubMed ID: 23896980
[TBL] [Abstract][Full Text] [Related]
31. Management of cutaneous manifestations of lupus erythematosus: A systematic review.
Fairley JL; Oon S; Saracino AM; Nikpour M
Semin Arthritis Rheum; 2020 Feb; 50(1):95-127. PubMed ID: 31526594
[TBL] [Abstract][Full Text] [Related]
32. Guideline for the diagnosis, treatment and long-term management of cutaneous lupus erythematosus.
Lu Q; Long H; Chow S; Hidayat S; Danarti R; Listiawan Y; Deng D; Guo Q; Fang H; Tao J; Zhao M; Xiang L; Che N; Li F; Zhao H; Lau CS; Ip FC; Ho KM; Paliza AC; Vicheth C; Godse K; Cho S; Seow CS; Miyachi Y; Khang TH; Ungpakorn R; Galadari H; Shah R; Yang K; Zhou Y; Selmi C; Sawalha AH; Zhang X; Chen Y; Lin CS
J Autoimmun; 2021 Sep; 123():102707. PubMed ID: 34364171
[TBL] [Abstract][Full Text] [Related]
33. Unusual severe radiation-induced toxicity in a patient with discoid lupus erythematosus: A case report and critical review of the literature.
Allali S; Chasset F; Kirova Y; Saint-Martin C; Moguelet P; Fourquet A; Beddok A
Cancer Radiother; 2022 Jun; 26(4):594-598. PubMed ID: 34728115
[TBL] [Abstract][Full Text] [Related]
34. Cutaneous Lupus Erythematosus in Children.
Tsang V; Leung AKC; Lam JM
Curr Pediatr Rev; 2021; 17(2):103-110. PubMed ID: 33655840
[TBL] [Abstract][Full Text] [Related]
35. Epidemiology of cutaneous lupus erythematosus and the associated risk of systemic lupus erythematosus: a nationwide cohort study in Denmark.
Petersen MP; Möller S; Bygum A; Voss A; Bliddal M
Lupus; 2018 Aug; 27(9):1424-1430. PubMed ID: 29788808
[TBL] [Abstract][Full Text] [Related]
36. Interferon-α stimulates TRAIL expression in human keratinocytes and peripheral blood mononuclear cells: implications for the pathogenesis of cutaneous lupus erythematosus.
Zahn S; Rehkämper C; Ferring-Schmitt S; Bieber T; Tüting T; Wenzel J
Br J Dermatol; 2011 Nov; 165(5):1118-23. PubMed ID: 21711324
[TBL] [Abstract][Full Text] [Related]
37. Selective Janus Kinase 1 Inhibition Is a Promising Therapeutic Approach for Lupus Erythematosus Skin Lesions.
Fetter T; Smith P; Guel T; Braegelmann C; Bieber T; Wenzel J
Front Immunol; 2020; 11():344. PubMed ID: 32194562
[TBL] [Abstract][Full Text] [Related]
38. Association Between Drug Use and Subsequent Diagnosis of Lupus Erythematosus.
Haugaard JH; Kofoed K; Gislason G; Dreyer L; Egeberg A
JAMA Dermatol; 2020 Nov; 156(11):1199-1207. PubMed ID: 32876672
[TBL] [Abstract][Full Text] [Related]
39. Novel biological therapeutic approaches to cutaneous lupus erythematosus.
Tayer-Shifman OE; Rosen CF; Wakani L; Touma Z
Expert Opin Biol Ther; 2018 Oct; 18(10):1041-1047. PubMed ID: 30118337
[TBL] [Abstract][Full Text] [Related]
40. An Update on the Pathogenesis of Cutaneous Lupus Erythematosus and Its Role in Clinical Practice.
Patel J; Borucki R; Werth VP
Curr Rheumatol Rep; 2020 Aug; 22(10):69. PubMed ID: 32845411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
